Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions

被引:0
|
作者
Slatter, JG [1 ]
Su, P [1 ]
Sams, JP [1 ]
Schaaf, LJ [1 ]
Wienkers, LC [1 ]
机构
[1] PHARMACIA & UPJOHN CO,CLIN PHARMACEUT,KALAMAZOO,MI 49007
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human hepatic microsomes were used to investigate the carboxylesterase-mediated bioactivation of CPT-11 to the active metabolite, SN-38, SN-38 formation velocity was determined by HPLC over a concentration range of 0.25-200 mu M CPT-11. Biphasic Eadie Hofstee plots were observed in seven donors, suggesting that two isoforms catalyzed the reaction. Analysis by nonlinear least squares regression gave K-M estimates of 129-164 mu M with a V-max of 5.3-17 pmol/mg/min for the low affinity isoform. The high affinity isoform had K-M estimates of 1.4-3.9 mu M with V-max of 1.2-26 pmol/mg/min. The low K-M carboxylesterase may be the main contributor to SN-38 formation at clinically relevant hepatic concentrations of CPT-11. Using standard incubation conditions, the effects of potential inhibitors of carboxylesterase-mediated CPT-11 hydrolysis were evaluated at concentrations greater than or equal to 21 mu M. Positive controls bis-nitrophenylphosphate (BNPP) and physostigmine decreased CPT-11 hydrolysis to 1.3-3.3% and 23% of control values, respectively. Caffeine, acetylsalicylic acid, coumarin, cisplatin, ethanol, dexamethasone, 5-fluorouracil, loperamide, and prochlorperazine had no statistically significant effect on CPT-11 hydrolysis. Small decreases were observed with metoclopramide (91% of control), acetaminophen (93% of control), probenecid (87% of control), and fluoride (91% of control). Of the compounds tested above, based on these in vitro data, only the potent inhibitors of carboxylesterase (BNPP, physostigmine) have the potential to inhibit CPT-11 bioactivation if administered concurrently. The carboxylesterase-mediated hydrolysis of alpha-naphthyl acetate (alpha-NA) was used to determine whether CPT-11 was an inhibitor of hydrolysis of high turnover substrates of carboxylesterases. Inhibition of alpha-NA hydrolysis by CPT-11 was determined relative to positive controls BNPP and NaF. Incubation with microsomes pretreated with CPT-11 (80-440 mu M) decreased alpha-naphthol formation to approximately 80% of control at alpha-NA concentrations of 50-800 mu M. The inhibitors BNPP (360 mu M) and NaF (500 mu M) inhibited alpha-naphthol formation to 9-10% of control and to 14-20% of control, respectively. Therefore, CPT-11-sensitive carboxylesterase isoforms may account for only 20% of total alpha-NA hydrolases. Thus, CPT-11 is unlikely to significantly inhibit high turnover, nonselective substrates of carboxylesterases.
引用
收藏
页码:1157 / 1164
页数:8
相关论文
共 35 条
  • [31] Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
    deBruijn, P
    Verweij, J
    Loos, WJ
    Nooter, K
    Stoter, G
    Sparreboom, A
    JOURNAL OF CHROMATOGRAPHY B, 1997, 698 (1-2): : 277 - 285
  • [32] High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes
    Hanioka, N
    Jinno, H
    Nishimura, T
    Ando, M
    Ozawa, S
    Sawada, J
    BIOMEDICAL CHROMATOGRAPHY, 2001, 15 (05) : 328 - 333
  • [33] Genetic predisposition to the metabolism of irinotecan (CPT-11) - Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
    Iyer, L
    King, CD
    Whitington, PF
    Green, MD
    Roy, SK
    Tephly, TR
    Coffman, BL
    Ratain, MJ
    JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04): : 847 - 854
  • [34] CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk
    Chen, Pinjia
    Luo, Xiaoyong
    Nie, Peipei
    Wu, Baoyan
    Xu, Wei
    Shi, Xinpeng
    Chang, Haocai
    Li, Bing
    Yu, Xiurong
    Zou, Zhengzhi
    FREE RADICAL BIOLOGY AND MEDICINE, 2017, 104 : 280 - 297
  • [35] Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D
    Jinno, H
    Tanaka-Kagawa, T
    Hanioka, N
    Saeki, M
    Ishida, S
    Nishimura, T
    Ando, M
    Saito, Y
    Ozawa, S
    Sawada, JI
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) : 108 - 113